TriSalus Life Sciences (TLSI) Equity Ratio (2020 - 2026)

TriSalus Life Sciences (TLSI) has 7 years of Equity Ratio data on file, last reported at 0.18 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 115.03% year-over-year to 0.18; the trailing twelve-month figure through Mar 2026 stood at 0.18 (up 115.03% YoY), and the FY2025 full-year result was 0.96, up 11.28% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.18, up from 0.96 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.25 in Q3 2023 and bottomed at 16.21 in Q2 2023.
• The 5-year median for Equity Ratio is 0.78 (2024), against an average of 2.57.
• Peak annual rise in Equity Ratio reached 140.35% in 2023, while the deepest fall reached 2683.27% in 2023.
• A 5-year view of Equity Ratio shows it stood at 8.05 in 2022, then soared by 86.34% to 1.1 in 2023, then gained by 1.82% to 1.08 in 2024, then rose by 11.28% to 0.96 in 2025, then surged by 118.83% to 0.18 in 2026.
• The last three Equity Ratio figures came in at 0.18 (Q1 2026), 0.96 (Q4 2025), and 0.73 (Q3 2025), per Business Quant data.

Peer Comparison